Studies

Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety.

PLoS medicine|2026|Chao A, Gilden A, Wadden T

Glucagon-like peptide-1 (GLP-1)-based medications, such as semaglutide and tirzepatide, have transformed obesity care. However, rising use brings concerns about side effects, long-term outcomes, and unregulated products. Ensuring safe access requires…

Semaglutide Tirzepatide

PMID: 41533690

Pharmacological Management of Diabesity: Current and Emerging Therapies.

Current obesity reports|2026|Galasso M et al.

PURPOSE OF REVIEW: This review aims to provide a comprehensive synthesis of current clinical evidence on the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and dual glucose-depend…

ReviewSemaglutide Tirzepatide

PMID: 41528611

Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA).

Alimentary pharmacology & therapeutics|2026|Ajmera V et al.

BACKGROUND/AIMS: Non-invasive test (NIT)-based assessment of eligibility and treatment response with semaglutide is needed to inform clinical practice guidance. Therefore, utilising a randomised, placebo-controlled study design, we evaluated the util…

Randomized Controlled TrialSemaglutide

PMID: 41527269

Combination of GLP-1 receptor agonist and Akkermansia muciniphila Akk11 reduces adiposity and ameliorates MASLD in T2D mice.

Cell & bioscience|2026|Gao K et al.

AIMS/HYPOTHESIS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease globally and is closely associated with type 2 diabetes (T2D) and obesity. Glucagon-like peptide-1 receptor agonists (GLP-1R…

Animal StudySemaglutide

PMID: 41526984

Semaglutide and tirzepatide in prediabetes: Evidence for diabetes prevention and cardiovascular protection.

Primary care diabetes|2026|Tentolouris A et al.

BACKGROUND: Prediabetes represents an intermediate stage in the dysglycemia continuum, associated with increased cardiometabolic risk but also substantial opportunity for prevention. The aim of this review was to summarize and critically evaluate the…

ReviewSemaglutide Tirzepatide

PMID: 41565568

Calculating cost per event avoided using a composite number needed to treat.

Journal of medical economics|2026|Toliver J et al.

OBJECTIVE: Number needed to treat (NNT) and cost per event avoided (CPEA) are measures used to represent the clinical and economic value of chronic treatments and are commonly calculated based on primary endpoints from trials. This approach, although…

Semaglutide

PMID: 41562647

Coverage is the Key to Realizing the Promise of Semaglutide.

Journal of general internal medicine|2026|Gasoyan H, Rothberg M

Semaglutide

PMID: 41559293

Efsubaglutide Alfa attenuates metabolic dysfunction-associated steatohepatitis in mice with improvements in second harmonic generation-derived fibrosis features.

Diabetes, obesity & metabolism|2026|Wang Y et al.

AIMS: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with limited effective treatments. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise for metabolic and hepatic benefits. This study eva…

Animal StudySemaglutide

PMID: 41555840

Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes.

Journal of diabetes investigation|2026|Omori Y et al.

INTRODUCTION: Recent studies have demonstrated that both oral semaglutide and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have beneficial effects on glycemic and weight management as well as providing renal and cardiovascular protection. Howe…

ObservationalSemaglutide

PMID: 41555812

Cardiac autonomic neuropathy in patients with SGA-treated schizophrenia: a randomized controlled trial of 30 weeks' treatment with semaglutide.

Cardiovascular diabetology. Endocrinology reports|2026|Ganeshalingam A et al.

BACKGROUND: Individuals with schizophrenia suffer from reduced life expectancy, primarily due to obesity-related metabolic disorders and cardiovascular disease (CVD). The presence of cardiac autonomic neuropathy (CAN) may contribute to CVD, but CAN i…

Semaglutide

PMID: 41555458

What is "triple strength" Wegovy, and why has the MHRA approved it?

BMJ (Clinical research ed.)|2026|Lang K

Semaglutide

PMID: 41554571

Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy.

American journal of physiology. Heart and circulatory physiology|2026|Muir K et al.

The search for effective adjuncts to procedural revascularization for patients with coronary artery disease (CAD) has revealed, after several successful outcomes trials, the substantial potential of glucagon-like peptide 1 (GLP-1) analogs such as sem…

Animal StudySemaglutide

PMID: 41553720

Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial.

PharmacoEconomics|2026|Bøg M et al.

BACKGROUND: Overweight and obesity is a prevalent and growing global health concern associated with a significant healthcare burden. With recent advancements in weight management interventions demonstrating cardioprotective benefits, there is a need…

Randomized Controlled TrialSemaglutide

PMID: 41553702

Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review.

Clinical obesity|2026|Urbina J et al.

Glucagon-like peptide-1 receptor agonists (GLP-1RA) such as semaglutide, liraglutide and tirzepatide are effective for obesity and type 2 diabetes mellitus (T2DM) but may predispose users to micronutrient deficiencies through appetite suppression, de…

ReviewSemaglutide Tirzepatide

PMID: 41549912

Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.

Lancet (London, England)|2026|Nauck M et al.

GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hy…

ReviewSemaglutide Tirzepatide

PMID: 41547366

Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety.

RETRACTION: Comparative efficacy of semaglutide versus liraglutide on weight loss and glycaemic control.

Pharmacological Management of Diabesity: Current and Emerging Therapies.

Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA).

Combination of GLP-1 receptor agonist and Akkermansia muciniphila Akk11 reduces adiposity and ameliorates MASLD in T2D mice.

Semaglutide and tirzepatide in prediabetes: Evidence for diabetes prevention and cardiovascular protection.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have potential to transform health outcomes for persons with bipolar disorder, schizophrenia, major depressive disorder and other serious mental illnesses by lengthening healthspan and reducing excess and premature mortality.

Calculating cost per event avoided using a composite number needed to treat.

Coverage is the Key to Realizing the Promise of Semaglutide.

Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction-associated steatohepatitis?

Efsubaglutide Alfa attenuates metabolic dysfunction-associated steatohepatitis in mice with improvements in second harmonic generation-derived fibrosis features.

Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes.

Cardiac autonomic neuropathy in patients with SGA-treated schizophrenia: a randomized controlled trial of 30 weeks' treatment with semaglutide.

What is "triple strength" Wegovy, and why has the MHRA approved it?

Web Exclusive. Annals On Call - Dulaglutide, Semaglutide, and Tirzepatide: How Do Gastrointestinal Adverse Effects Compare?

Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy.

Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial.

Micronutrient and Nutritional Deficiencies Associated With GLP-1 Receptor Agonist Therapy: A Narrative Review.

Expanding the Dermatologic Horizon of GLP-1 Receptor Agonists - Response to 'Dermatologic and Metabolic Benefits of Semaglutide in Psoriasis with Obesity: A Six-Month Prospective Cohort Study'.

Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.